Portable Butterfly iQ+ ultrasound system for University Hospital Bonn and Faculty of Medicine Students

As the first healthcare institution in Europe to do so, UKB and the Faculty of Medicine will provide medical students with personal, state-of-the-art, whole-body Butterfly iQ+ devices and implement Butterfly's Blueprint platform throughout UKB to further improve medical education, research and patient care.

The collaboration will include clinical integration at UKB and also evaluate impacts on care processes.

Bonn/Burlington (USA), February 22, 2023 -  For the first time in Europe, the University Hospital Bonn (UKB) and the Medical Faculty Bonn are using the advanced ultrasound system Butterfly Blueprint™ from the U.S.-headquartered digital health company, Butterfly Network, Inc., to teach medical and midwifery students at the UKB. The innovative, semiconductor chip-based Butterfly iQ+ can enable more informed diagnosis and treatment directly at the patient's bedside and support complex ultrasound training integrated into studies throughout the UKB campus.

Ultrasound diagnostics is one of the most important imaging procedures in medicine. It can be used to inform clinical assessment by nearly every medical specialty, and carries no side effects for patients. "However, ultrasound images are often not easy to interpret - which is why the UKB and the Medical Faculty promote early training and practical experience for medical and midwifery students," says PD Dr. Valentin Schäfer, head of rheumatology and the internal sonography center at the UKB. As the first healthcare institution in Europe to do so, UKB and the Faculty of Medicine will provide medical students with personal, state-of-the-art, whole-body Butterfly iQ+ devices and implement Butterfly's Blueprint platform throughout UKB to further improve medical education, research and patient care.

The medical school first engaged with the U.S. provider of this mobile ultrasound system in early 2020, becoming one of the largest contingents in Europe at the time, with more than 30 devices. The use of the portable devices has since proven successful: Numerous studies have been published from Bonn, which above all demonstrate the benefits in medical education. Butterfly is the only supplier to date to provide a single-probe, whole-body transducer with unique Ultrasound-on-Chip™  technology that converts a compatible smartphone or tablet into an imaging instrument, enabling the practical application of ultrasound information in the clinical workflows of medical staff. For that reason, the collaboration will now be expanded to include clinical integration at UKB and also evaluate impacts on care processes. The device fits in a pocket and is powered by a combination of cloud-connected software and hardware technology in a privacy-compliant manner that can be accessed via a mobile app.

"We are pleased that the Butterfly portable devices, with their combination of whole-body ultrasound probe, software, cloud connectivity, and integration into clinical and administrative systems and workflows, will be used at our UKB, further optimizing ultrasound diagnostics in teaching and patient care," said Prof. Wolfgang Holzgreve, Medical Director and CEO of UKB.

"Point-of-care ultrasound, i.e. ultrasound diagnostics close to the patient, will certainly be essential for our students in the future," says Prof. Bernd Weber, Dean of the Medical Faculty at the University of Bonn. "We accompany the personal equipment of our students with personal Butterfly devices with a specific curriculum, initially in the practical year, which incorporates ultrasound knowledge across disciplines and even more comprehensively." At UKB and the Medical School, Butterfly Network's portable imaging devices will be introduced as early as next summer semester and will be available to students in the practical year from then on.

"We are proud to collaborate with UKB and the Faculty of Medicine to further embed our technology into its healthcare system with enhanced access to training and education, affordable equipment, and practical encounter-based workflows that are uniquely offered with the Butterfly Blueprint system. Through this collaboration, students at this premier European medical institution will access state-of-the-art healthcare technology and educational assets to ultimately become proficient in using ultrasound information directly at the bedside," said Niki Montgomery, Sr. Vice President, Commercial Development at Butterfly Network, Inc.

PD Dr. Schäfer and Dr. Florian Recker, specialist in obstetrics and prenatal medicine at the UKB, are in charge of the project at the UKB and will provide scientific support. The start of the rollout begins with the new curriculum, which will be known as the BI-POCUS project (Bonn Internship Point-of-Care-Ultrasound) in the students' practical year.

Press contact:

Viola Röser
Press Officer at the University Hospital Bonn (UKB)
Communications and Media Office at Bonn University Hospital
Phone: +49 228 287- 10469
E-mail: viola.roeser@ukbonn.de

Liz Learned
Butterfly Network
Media@butterflynetwork.com

About the University Hospital Bonn: The UKB cares for about 500,000 patients per year, employs 8,800 people and has a balance sheet total of 1.5 billion euros. In addition to the more than 3,300 medical and dental students, a further 580 people are trained each year in numerous healthcare professions. The UKB is ranked number 1 among university hospitals (UK) in NRW in the science ranking as well as in the Focus clinic list and has the third highest case mix index (case severity index) in Germany.

About Butterfly Network: Founded in 2011 by Jonathan Rothberg, Ph.D., and listed on the New York Stock Exchange through a business combination with Longview Acquisition Corp, Butterfly created the world's first handheld, single probe whole-body ultrasound system using semiconductor technology, the Butterfly iQ+. Butterfly's mission is to democratize medical imaging and contribute to the aspiration of global health equity, making high-quality ultrasound affordable, easy-to-use, globally accessible and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Through its proprietary Ultrasound-on-Chip™ technology, Butterfly is paving the way for earlier detection and remote management of health conditions around the world. Butterfly iQ+ can be purchased today by trained healthcare practitioners in areas including, but not limited to, Africa, Asia, Australia, Europe, North America and South America; to learn more about available countries, visit: butterflynetwork.com/choose-your-country.

Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to financial results, future performance, development of products and services, and the size and potential growth of current or future markets for its products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company’s business, including issues relating to Omicron or other variants; the ability to recognize the anticipated benefits of the business combination; the Company’s ability to grow and manage growth profitably; the success, cost and timing of the Company’s product and service development activities; the potential attributes and benefits of the Company’s products and services; the degree to which our products and services are accepted by healthcare practitioners and patients for their approved uses; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing license, manufacture, supply and distribution agreements; manufacturing and supply of the Company’s products; the Company’s ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; changes in applicable laws or regulations; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical procedures conducted using its products and services; the Company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company’s ability to raise financing in the future; and other risks and uncertainties indicated from time to time in the Company’s most recent Annual Report on Form 10-K or in subsequent filings that it makes with the Securities and Exchange Commission. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions you not to place undue reliance upon any forward-looking statements, which speak only as of the date of this press release. The Company does not undertake or accept any obligation or undertake to release publicly any updates or revisions to any forward-looking statements to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which any such statement is based.